30. November 2016
Press Release: Zedira receives funding by the German Government for the development of transglutaminase inhibitors for the treatment of diabetic nephropathy
Darmstadt, November, 30th 2016
Zedira announced today that the BMBF will grant additional 1.5 million Euros funding to the company within the highly competitive SME-Innovative program over the next three years.
The aim of the project is for Zedira to develop small molecule tissue transglutaminase inhibitors that are orally bioavailable. Transglutaminase is considered to be a scientifically validated target in certain fibrotic diseases such as diabetic nephropathy. Kidney injury is one of the most severe complications of diabetes.
The funding will allow Zedira to expand its leadership in low-molecular-weight transglutaminase blockers. In fact, Zedira’s ZED1227 is the first transglutaminase blocker ever to be evaluated in clinical trials for celiac disease, and is currently in phase 1b trials. Additionally, the core biotech company has recently developed ZED3197, the first drug candidate to target blood coagulation factor XIII (F13, plasma transglutaminase). This compound (a peptidomimetic) has proved to be a potent anticoagulant without prolonging the bleeding time in an animal model of venous stasis and reperfusion. About Zedira:
The Darmstadt-based biotech company has a focus on transglutaminase-linked conditions in the arena of autoimmunity, fibrotic disease and thrombosis. The company develops, produces and markets specialized reagents and kits for research and development as well as for clinical diagnostics. Zedira is a portfolio company of the German High-Tech Gründerfonds.